Discovered along with EPZ005678 but shows better potency and oral bioavailability in animals. Treatment of mice bearing a lymphoma xenograft with mutant EZH2 reduces cell growth in a concentration dependent manner. FDA-approved for follicular lymphoma and epithelioid sarcoma with SNF5 deletions. This evidence concerns the gene EZH2 and lymphoma.